AR124337A1 - Formulaciones farmacéuticas de un profármaco fenólico agonista del trpv1 - Google Patents

Formulaciones farmacéuticas de un profármaco fenólico agonista del trpv1

Info

Publication number
AR124337A1
AR124337A1 ARP210103470A ARP210103470A AR124337A1 AR 124337 A1 AR124337 A1 AR 124337A1 AR P210103470 A ARP210103470 A AR P210103470A AR P210103470 A ARP210103470 A AR P210103470A AR 124337 A1 AR124337 A1 AR 124337A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical formulations
prodrug
phenolic
trpv1 agonist
methyl
Prior art date
Application number
ARP210103470A
Other languages
English (en)
Inventor
Susan Wollowitz
John F Donovan
Original Assignee
Concentric Analgesics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concentric Analgesics Inc filed Critical Concentric Analgesics Inc
Publication of AR124337A1 publication Critical patent/AR124337A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1412—Containers with closing means, e.g. caps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/19—Syringes having more than one chamber, e.g. including a manifold coupling two parallelly aligned syringes through separate channels to a common discharge assembly

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento, se proporcionan formulaciones farmacéuticas que comprenden el canal iónico de potencial receptor 1 transitorio de la subfamilia vainilloide (TRPV1), o una sal farmacéuticamente aceptable de este. Reivindicación 1: Una composición farmacéutica sólida caracterizada porque comprende: (a) de aproximadamente 0,25 mg a aproximadamente 125 mg de 2-((metilamino)metil)piperidina-1-carboxilato de (E)-2-metoxi-4-((8-metilnon-6-enamido)metil)fenil, o una sal farmacéuticamente aceptable de este; y (b) de aproximadamente 0,25 mg a aproximadamente 75 mg de un agente amortiguador.
ARP210103470A 2020-12-14 2021-12-13 Formulaciones farmacéuticas de un profármaco fenólico agonista del trpv1 AR124337A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063125316P 2020-12-14 2020-12-14

Publications (1)

Publication Number Publication Date
AR124337A1 true AR124337A1 (es) 2023-03-15

Family

ID=82058515

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103470A AR124337A1 (es) 2020-12-14 2021-12-13 Formulaciones farmacéuticas de un profármaco fenólico agonista del trpv1

Country Status (5)

Country Link
US (1) US20240050421A1 (es)
EP (1) EP4263495A1 (es)
AR (1) AR124337A1 (es)
TW (1) TW202237106A (es)
WO (1) WO2022132649A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9359316B1 (en) * 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
WO2017205534A1 (en) * 2016-05-25 2017-11-30 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia

Also Published As

Publication number Publication date
WO2022132649A1 (en) 2022-06-23
US20240050421A1 (en) 2024-02-15
TW202237106A (zh) 2022-10-01
EP4263495A1 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
NI201100158A (es) Formulaciones de 4 - amino - 2 - (2, 6 - dioxopiperidina - 3 - il) isoindolina - 1, 3 - diona
ES2546847T3 (es) Formulaciones de un inhibidor de la Src/Abl
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
AR112271A1 (es) Composiciones que comprenden un inhibidor de arn polimerasa y ciclodextrina para el tratamiento de infecciones virales
AR052153A1 (es) Composiciones y metodos para la estabilizacion de ingredientes farmaceuticos activos
PE20120476A1 (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
ECSP088240A (es) Composición de trazodona para administración una vez por día
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
AR063096A1 (es) Pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina
AR056873A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas
AR109357A2 (es) Composición farmacéutica parenteral con tolerancia en el sitio de inyección
UY27598A1 (es) Composiciones farmacéuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada
AR058901A1 (es) Compuestos derivados de hidantoina, utiles para el tratamiento de trastornos inflamatorios y composicion farmaceutica que los comprende
CO2021005221A2 (es) Formulación basada en ciclodextrina de un inhibidor de bcl-2
CL2021001956A1 (es) Formulaciones de inmunoconjugado anti-cd79b estables. (divisional solicitud 202002624)
CO2021010493A2 (es) Compuestos de halo-alilamina y uso de los mismos
PE20150773A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilefrina
ECSP22040362A (es) Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x
MX2022008914A (es) Compuestos terapeuticos, formulaciones y usos de los mismos.
CL2022000875A1 (es) Inhibidores del factor d del complemento para administración oral
ECSP22040921A (es) Composición farmacéutica que comprende selexipag
AR062979A1 (es) Formulaciones orales liofilizadas de desintegracion rapida de un antagonista del receptor de trombina
CL2021001621A1 (es) Formulaciones orales de branaplam
AR124337A1 (es) Formulaciones farmacéuticas de un profármaco fenólico agonista del trpv1
ECSP055625A (es) Profarmaco inhibidor de beta-lactamasa

Legal Events

Date Code Title Description
FB Suspension of granting procedure